8 articles
FDA-approved methylene blue reduced delirium-like behavior in surgical mice by suppressing neuroinflammation and repairing the blood-brain barrier.
A primate study shows methylene blue treats fatal cerebral malaria and uncovers neutrophil-linked genes as diagnostic biomarkers.
A 4-week-old infant developed severe methemoglobinemia after EMLA cream was applied for circumcision, highlighting hidden dangers of topical anesthetics.
A 2025 review examines how methylene blue's nitric oxide inhibition can restore vascular tone in septic and vasoplegic shock patients.
Adding methylene blue to ropivacaine in a serratus anterior plane block significantly prolongs pain relief up to 72 hours post-op.
A meta-analysis of 15 studies finds methylene blue therapy significantly reduces mortality in ICU septic shock patients, with hemodynamic benefits.
Current labeling urges nursing mothers to pause breastfeeding for 8 days after methylene blue, but the underlying evidence is thin.
A comprehensive review reveals methylene blue's expanding role from toxicology emergencies to perioperative care, neurology, and oncology.
